Merz acquire BioForm Medical

Merz Pharma have agreed to acquire BioForm Medical for $253m, expanding its presence in cosmetic pharmaceuticals

Merz Pharma Group have agreed to acquire BioForm Medical Inc (BFRM) for $253m, expanding its cosmetic pharmaceuticals portfolio. The privately held German pharmaceutical company already has a presence in anti-ageing skincare with their product Belotero - the world's first monophasic hyaluronic acid dermal filler with patented CPM technology.

Merz will pay $5.45 per BioForm share, a 60 per cent premium to the company's Thursday closing price.

BioForm, which went public in late 2007, specialises in injectable drugs to improve the appearance of the skin, including treatment of wrinkles and folds, as well as varicose veins. The company is non profitable, though sales have been improving and last November BioForm narrowed its loss forecast for its fiscal year ending June 30.

6th January 2010

PME Digital Edition

Featured jobs

Medical Writer: Salary TBC

Associate Medical Director: Excellent PTO, bonus and 401k package

Medical Writer: Bonus Scheme, PTO &Private Healthcare

SAE – Healthcare PR – Award-Winning Consultancy: Salary TBC

Business Director: Competitive Salary Offered

Account Manager- Healthcare Advertising: Negotiable

Account Director – Healthcare Marketing – Berks: Salary TBC

Medical (Scientific) Director: £120, 000 benefits

Account Manager / Account Director: Competative

Experienced Medical Writers: Competitive Salary and Benefits

Account Executive/ Senior Account Executive: competitive Salary Offfered

Associate Director: £75, 000-90, 000

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Senior Account Manager: Competitive Salary Offered

Account Director: Competitive Salary Offered

Senior Editorial Assistant – Greater Manchester: DOE

Healthcare Communications Account Directors x 2: Salary TBC

CALLING ALL SENIOR HEALTHCARE PR FREELANCERS!!!!! ACCOUNT DIRECT...: EXCELLENT DAY RATES AVAILABLE

Editorial Manager - MedComms: DOE

Account Manager: Negotiable

Digital Communications Lead, Healthcare Brand and Medical Commun...: up to £50K

Systematic Reviewer - Oxford: Negotiable

Business Development Director – Health Education: excellent commission

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Account Manager / Senior Account Manager: 35, 000-40, 000

Is China ready for a pharmaceutical gold rush?: Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance: Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis: Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...